3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
2708
Lung Neoplasms
2267
Small Cell Lung Carcinoma
452
Breast Neoplasms
394
Neoplasms
348
Colorectal Neoplasms
245
Ovarian Neoplasms
208
Pancreatic Neoplasms
196
Melanoma
196
Prostatic Neoplasms
187
Adenocarcinoma of Lung
184
Neoplasm Metastasis
177
Head and Neck Neoplasms
175
Mesothelioma, Malignant
152
Esophageal Neoplasms
144
Carcinoma, Renal Cell
142
Stomach Neoplasms
141
Colonic Neoplasms
138
Urinary Bladder Neoplasms
124
Mesothelioma
121
Squamous Cell Carcinoma of Head and Neck
115
Uterine Cervical Neoplasms
97
Sarcoma
86
Brain Neoplasms
86
Kidney Neoplasms
82
Carcinoma, Hepatocellular
71
Liver Neoplasms
68
Adenocarcinoma, Bronchiolo-Alveolar
68
Rectal Neoplasms
64
Pleural Effusion, Malignant
64
Interventions
osimertinib
1
Gefitinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
×
Thoracic
×
Clear all
NCT02296125
2026-04-21
FLAURA
AstraZeneca
Phase 3
Completed
674 enrolled
21 charts
1 FDA